SCHEMBL17757965

SCHEMBL17757965

CON1/C(=N/Cc2cccc(Cl)c2)C2(CCCCC2)Nc2cc(N(C)C)ncc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACAT2 Q9BWD1 2/20 0.38
▸ TSHR P16473 5/20 0.35
▸ FSHR P23945 5/20 0.35
▸ HTR2A P28223 2/20 0.33
▸ HTR2C P28335 2/20 0.33
▸ HTR2B P41595 2/20 0.33
▸ CHRM4 P08173 1/20 0.32
▸ ADRB1 P08588 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ CHRM5 P08912 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ CHRM3 P20309 1/20 0.32
▸ FPR3 P25089 1/20 0.32
▸ HTR1D P28221 1/20 0.32
▸ HTR1B P28222 1/20 0.32
▸ HTR1E P28566 1/20 0.32
▸ GPR183 P32249 1/20 0.32
▸ HTR7 P34969 1/20 0.32
▸ HRH1 P35367 1/20 0.32
▸ DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17757987 0.93 ACAT2 (0.38) ACAT2TSHRFSHRHTR2AHTR2C
SCHEMBL17757272 0.72 ACAT2 (0.50) ACAT2TSHRFSHRSIGMAR1KMT2A
SCHEMBL17757989 0.70 ACAT2 (0.48) ACAT2TSHRFSHRHTR2AHTR2C
SCHEMBL17757988 0.68 ACAT2 (0.39) ACAT2TSHRFSHRSIGMAR1
SCHEMBL17757968 0.66 ACAT2 (0.48) ACAT2HTR2AHTR2CHTR2BCHRM4
SCHEMBL17757966 0.65 ACAT2 (0.39) ACAT2SIGMAR1
SCHEMBL17757949 0.64 ACAT2 (0.43) ACAT2SIGMAR1MEN1KMT2A
SCHEMBL17757951 0.64 ACAT2 (0.56) ACAT2HTR2AHTR2CHTR1AHTR7
SCHEMBL17757268 0.64 ACAT2 (0.46) ACAT2SIGMAR1MEN1KMT2A
SCHEMBL17757964 0.64 ACAT2 (0.46) ACAT2HTR2AHTR2CHTR2BCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
WO-2016075137-A1 SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 ACAT2 1935/4885TSHR 1100/4885FSHR 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback